Alto Neuroscience, Inc. ("Alto") , a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a favorable ...

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX100 to 800 Patients SHIELD II Enrolled more than ...

Introduction Blood and blood products are essential for patients in need of transfusion therapy, especially those undergoing ...

Q4 2024 Earnings Call Transcript February 3, 2025 Operator: Good morning, and welcome to the IDEXX Laboratories’ Fourth ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

Presentation Operator Good morning, and welcome to the IDEX Laboratories 4th-Quarter 2024 Earnings Conference Call ...

Gabbard advances: Senators voted on party lines to push forward the nomination of Tulsi Gabbard, a former Democratic member ...

Throughout 2025, Emerita will continue with its metallurgical assessment. Samples for El Cura were submitted to the lab in ...

Annual product data found the company's innovative patient affordability solutions achieved these noteworthy successes in 2024: "2024 was a pivotal year for our patient affordability business," said ...

financial account type, patient account number, medical record number, health insurance information, medical treatment information, medical claim information and Social Security number,” the ...